{
    "pmcid": "8537675",
    "qa_pairs": {
        "How can nanobodies targeting the RBD of the spike protein effectively neutralize the virus?": [
            "By preventing ACE2 binding.",
            "By enhancing viral entry into host cells.",
            "By increasing the mutation rate of the virus.",
            "By facilitating conformational changes necessary for viral entry."
        ],
        "What is a significant characteristic of the B.1.351 (Beta) variant concerning immune evasion?": [
            "It contains E484K and K417N mutations, leading to significant immune escape.",
            "It has the D614G mutation, increasing viral infectivity.",
            "It lacks mutations in the RBD, making it less immune evasive.",
            "It primarily affects the furin cleavage site, reducing transmissibility."
        ],
        "What is the role of the SARS-CoV-2 spike protein in viral entry into host cells?": [
            "It facilitates viral entry by binding to the human ACE2 receptor.",
            "It acts as a decoy to distract the immune system.",
            "It degrades host cell membranes to allow viral entry.",
            "It directly injects viral RNA into the host cell nucleus."
        ],
        "Which mutation in the SARS-CoV-2 spike protein is associated with increased viral infectivity and higher viral loads globally?": [
            "D614G Mutation",
            "N501Y Mutation",
            "E484K Mutation",
            "K417N Mutation"
        ],
        "Why is continuous monitoring of spike protein mutations crucial for therapeutic and preventive strategies?": [
            "To develop effective therapeutics and vaccines capable of countering emerging variants.",
            "To ensure the spike protein remains stable and unchanging.",
            "To reduce the mutation rate of the virus.",
            "To eliminate the need for vaccine updates."
        ]
    }
}